Cancer therapy based on a mechanism of action for controlling the immune system and the resulting patent portfolio.

Despite decades of research, current cancer therapies extend survival but often do not actually cure the disease. Immune cell based therapy is described here that can eliminate tumor cells without the toxicity associated with chemotherapy or allogeneic bone marrow transplant (BMT). Allogeneic BMT has beneficial graft vs.

Is transport with platelet GP IIb/IIIa inhibition for primary percutaneous coronary intervention more efficient than on-site thrombolysis in patients with STEMI admitted to community hospitals? Randomised study. Early results.

Introduction: The advantage of primary percutaneous coronary intervention (pPCI) in the management of ST-elevation myocardial infarction (STEMI) over thrombolytic therapy has been demonstrated. However, an optimal medical treatment of STEMI patients admitted to regional hospitals without catheterisation facilities has not yet been established. Delay in initiation of pPCI resulting from transportation to the catheterisation laboratory may diminish the benefits of such therapy in comparison with thrombolysis administered in a regional hospital.

Changes in C-reactive protein levels following coronary stent implantation depend on the extent of periprocedural arterial injury.

Background: Coronary stenting is associated with acute inflammation within the arterial wall followed by neointimal growth. Acute inflammatory response is expressed by a marked systemic elevation of the inflammatory biomarker C-reactive protein (CRP). It has been shown that the degree and extent of CRP increase may be related to clinical presentation or periprocedural treatment.

[Pathologic splenic rupture in the course of non-Hodgkin's lymphoma].

Pathologic rupture of the spleen is an uncommon but life-threatening complication of some malignant diseases. This paper presents a case of splenic rupture which occurred in a man with non-Hodgkin's lymphoma. We briefly discuss etiology, pathophysiology, symptoms and treatment of this complication.

Treatment for primary refractory Hodgkin's disease: a comparison of high-dose chemotherapy followed by ASCT with conventional therapy.

Our previously published study showed promising results of autologous stem cell transplantation (ASCT) in patients with primary resistant Hodgkin's disease (HD). Probabilities of overall survival (OS) and progression-free survival (PFS) at 3 years were 55 and 36%, respectively. The present study was undertaken to compare these results with conventionally treated patients and thus evaluate therapeutic options.